New! View global litigation for patent families

US20070010570A1 - Medical Compositions for Intravesical Treatment of Bladder Cancer - Google Patents

Medical Compositions for Intravesical Treatment of Bladder Cancer Download PDF

Info

Publication number
US20070010570A1
US20070010570A1 US11531535 US53153506A US2007010570A1 US 20070010570 A1 US20070010570 A1 US 20070010570A1 US 11531535 US11531535 US 11531535 US 53153506 A US53153506 A US 53153506A US 2007010570 A1 US2007010570 A1 US 2007010570A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
bladder
activity
present
invention
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11531535
Inventor
Bastiaan Nuijen
Ernie Pfadenhauer
Jos Beijnen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/908Leukemia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/951Powders, granules or particles of specified mesh or particle size
    • Y10S514/952Wettable
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/97Containing designated ingredient to stabilize an active ingredient

Abstract

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • [0001]
    This application is a continuation of U.S. patent application Ser. No. 11/096,566 filed Apr. 1, 2005 which claims benefit to U.S. patent application Ser. No. 10/285,783 filed Nov. 1, 2002, now U.S. Pat. No. 6,894,071 which claims the benefit of U.S. Provisional Application No. 60/344,446, filed Nov. 1, 2001, the entire contents of which are hereby incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Bladder cancer accounts for approximately 2% of all malignant cancers and is the fifth and tenth most common cancer in men and women, respectively. The American Cancer Society estimated that 54,500 new cases and 11,700 deaths would have occurred in 1997. Superficial bladder cancers (pTa, pT1 and CIS) account for 70-80% of cancers at first presentation. Management of superficial bladder cancer may be achieved by endoscopic surgical resection often followed by a course of adjuvant intravesical chemotherapy or immunotherapy with the aim of both eradicating remaining tumor cells and preventing tumor recurrence (Herr H W (1987) Intravesical therapy—a critical review. Urol Clin N Am 14:399-404). Both anti-neoplastics (Mitomycin C [MMC], epirubicin and thioTEPA) and immunotherapy (BCG) administered intravesically are effective at reducing tumor recurrence rates although it is unclear whether disease progression to muscle invasive tumors is prevented (Newling D (1990) Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group, Br J Cancer 61:497-499; Oosterlink et al. (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749-752). This observation in conjunction with the fact that mortality from bladder cancer is still high underscores the need to develop more effective therapeutic agents (Oosterlink et al. 1993).
  • [0003]
    One such therapeutic agent is MMC which belongs to a class of compounds known as bioreductive drugs (Workman 1994). MMC represents one of the antineoplastic agents used to treat superficial bladder cancers (Maffezzini et al, 1996, Tolley et al, 1996). MMC is activated to a cytotoxic species by cellular reductases although the role of specific reductase enzymes involved in bioreductive activation remains poorly defined and controversial (Cummings et al, 1998a). This is particularly true for the enzyme NQO1 (NAD(P)H:Quinone oxidoreductase, EC 1.6.99.2) which is a cytosolic flavoprotein which catalyses the two electron reduction of various quinone based compounds using either NADH or NADPH as electron donors (Schlager and Powis, 1988, Siegel et al, 1990). The structurally related compound E09 (5-aziridinyl-3-hydroxymethyl-1methyl-2-[1H-indole-4,7-dione]prop-(3-en-a-ol), is however a much better substrate for NQO1 than MMC (Walton et al, 1991) and a good correlation exists between NQO1 activity and chemosensitivity in vitro under aerobic conditions (Robertson et al, 1994, Fitzsimmons et al, 1996, Smitkamp-Wilms et al, 1994). Under hypoxic conditions however, EO9's properties are markedly different with little or no potentiation of EO9 toxicity observed in NQO1 rich cells (Plumb and Workman, 1994). In NQO1 deficient cell lines however, large hypoxic cytotoxicity ratios have been reported (Workman, 1994). Therefore, EO9 has the potential to exploit the aerobic fraction of NQO1 rich tumors or the hypoxic fraction of NQO1 deficient tumors (Workman, 1994).
  • [0004]
    EO9 has been clinically evaluated but despite reports of three partial remissions in phase I clinical trials, no activity was seen against NSCLC, gastric, breast, pancreatic and colon cancers in subsequent phase II trials (Schellens et al, 1994, Dirix et al, 1996). These findings are particularly disappointing in view of the preclinical studies (Hendriks et al, 1993) together with reports that several tumor types have elevated NQO1 levels (Malkinson et al, 1992, Smitkamp-Wilms et al, 1995, Siegel et al, 1998). Several possible explanations have been proposed to explain E09's lack of clinical efficacy (Connors, 1996, Phillips et al, 1998). Recent studies have demonstrated that the failure of E09 in the clinic may not be due to poor pharmacodynamic interactions but may be the result of poor drug delivery to tumors (Phillips et al, 1998). The rapid plasma elimination of E09 (tl/z=10 min in humans) in conjunction with poor penetration through multicell layers suggests that E09 will not penetrate more than a few microns from a blood vessel within its pharmacokinetic lifespan (Schellens et al, 1994, Phillips et al, 1998). Intratumoural administration of E09 to NQ01 rich and deficient tumors produced significant growth delays (although a distinction between damage to the aerobic or hypoxic fraction was not determined) suggesting that if E09 can be delivered to tumors, therapeutic effects may be achieved (Cummings et al, 1998b). While these undesirable characteristics are a serious setback for the treatment of systemic disease, paradoxically they may be advantageous for treating cancers which arise in a third compartment such as superficial bladder cancer. In this scenario, drug delivery is not problematical via the intravesical route and the penetration of E09 into avascular tissue can be increased by maintenance of therapeutically relevant drug concentrations within the bladder (using a one hour instillation period for example). While this method of instilling EO9 within the bladder may be useful, there still remains a need for drug delivery vehicles that are capable of delivering an effective amount of EO9 within the bladder.
  • BRIEF SUMMARY OF THE INVENTION
  • [0005]
    In a broad aspect, the present invention is directed to compositions for treating cancer. More specifically, the compositions of the present invention comprise pharmaceutical products formulated for intravesical instillation to treat bladder cancer. The pharmaceutical products comprise bioredutive alkylating indoloquinone with anti-tumor effects such as, but not limited to, 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) and a formulation vehicle. The formulation vehicles of the present invention improves the physical characteristics of the solution such as solubility, lyophilization, and ease of reconstitution of the lyophilized solution.
  • [0006]
    According to one embodiment of the present invention, the composition of the present invention comprises 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (EO9) and a formulation vehicle. According to one embodiment, the formulation vehicle is a mixture of tert-butanol and water. In another embodiment, the formulation vehicle is a mixture of ethanol and water. In yet another embodiment, the formulation vehicle is 2-hydroxypropyl-β-cyclodextrin. These composition embodiments of the present invention can be lyophilized by techniques known or developed in the art. The lyophilized compositions of the present invention are
  • [0007]
    According to another embodiment of the present invention, the composition of the present invention comprises EO9 and a coating agent. The coating agent allows for better adhesion of the composition to the bladder wall. Consequently, the composition and, in particular, the EO9 contacts and may be able to penetrate the avascular tissue that comprises for a time sufficient to treat the bladder cancer. In one embodiment of the present invention, the coating agent is propylene glycol. In other exemplary embodiments of the present invention, the coating agent can be selected from the group consisting of hydroxypropylcellulose, carboxymethylcellulose, chitosan hydrochloride, lectin, or polycarbophil. In yet another embodiment of the present invention, the compositions of the present invention can be delivered to the bladder wall by a liposome. In another embodiment, the compositions of the present invention can be delivered to the bladder wall by a microsphere. In another embodiment, the compositions of the present invention can be delivered to a patient intravenously.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0008]
    The embodiments of the present invention are directed to compositions for treating bladder cancer via intravesical instillation. According to one embodiment, the composition of the present invention comprises 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (EO9) and a formulation vehicle. The formulation vehicles of the present invention are solvents that improves the solubility and stability of EO9. In a broad aspect of the present invention, the formulation vehicles of the present invention can be a mixture of an alcohol and water. According to the various embodiments of the present invention, EO9 dissolves in the formulation vehicles without physical manipulation such as grinding. Because the compositions of the present invention are capable of dissolving greater amounts of EO9, additional flexibility with respect to dosage units is achieved. According to one embodiment, a content of 8.0 mg of EO9 per dosage unit is contemplated. In other embodiments, instillation doses range from approximately 0.5 mg to approximately 16 mg in a total volume of 40 mL.
  • [0009]
    In addition to improving the solubility of EO9, the formulation vehicles of the present invention are good lyophilization vehicles. For example, the formulation vehicles of the present invention minimizes the time to lyophilize the compositions of the present invention. Accordingly, in one embodiment of the present invention, it is possible to lyophilize the compositions of the present invention in less than approximately 4.5 days. Furthermore, the compositions of the present invention are stable after undergoing lyophilization (see table 4). It is believed that the formulation vehicles of the present invention minimize the crystallization of EO9 during the lyophilization process. Consequently, by reducing the amount of crystallization of EO9, a smaller volume of fluid is required to reconstitute the compositions of the present invention. As a result, a larger batch size can be achieved due to the reduced reconstitution volumes for the lyophilized composition.
  • [0010]
    According to one embodiment, the composition of the present invention comprises EO9 and a formulation vehicle comprising tert-butanol. According to another embodiment of the present invention, the formulation vehicle comprises mixture of ethanol and water. In yet another embodiment, the formulation vehicle is 2-hydroxypropyl-β-cyclodextrin. In one exemplary embodiment, the formulation vehicle comprises 40% tert-butanol in water. As those skilled in the art will appreciate, the amount of tert-butanol may be varied. The tert-butanol solution better dissolves EO9 as compared to water. By utilizing a tert-butanol formulation vehicle, solubility of EO9 is at least 9.5 mg/ml whereas the solubility of EO9 is approximately 0.2 mg/ml in water. Consequently, a smaller volume of the tert-butanol is required to dissolve a given amount of EO9. Additionally, a greater amount of EO9 may be dissolved in a given solution. That is, the compositions of the present invention will have a higher concentration of EO9 as compared to a solution where EO9 is dissolved in water.
  • [0011]
    According to another embodiment of the present invention, the composition comprises, EO9, a formulation vehicle, and a bulking agent. In one exemplary embodiment, lactose can be utilized as the bulking agent. As those skilled in the art will appreciate, it is contemplated that other bulking agents known or developed in the art may be utilized. According to another exemplary embodiment, the composition of the present invention can be buffered. In one embodiment, the composition is buffered to a pH ranging from approximately 9 to approximately 9.5. The composition can be buffered with any known or developed buffering agents. The compositions of the present invention can either be compounded for intravesical delivery or lyophilized. As those skilled in the art will appreciate, the compositions of the present invention can be lyophilized by those methods known or developed in the art. The lyophilized compositions can be reconstituted by a reconstitution vehicle. According to one exemplary embodiment, the reconstitution vehicle comprises 2% sodium bicarbonate, 0.02% disodium edetate and propylene glycol: water (60:40 V/V). This reconstitution vehicle dissolves the lyophilized composition of the present invention and produces a stable solution for administration for up to 24 hours. Additionally, the reconstitution vehicle of the present invention provides an ampoule having an extractable volume of 5 mL of reconstituted EO9 comprising propylene glycol/water/sodium bicarbonate/sodium edetate 60/40/2/0.02% v/v/w/w.
  • [0012]
    In another aspect of the present invention, the compositions of the present invention also comprises coating agents. The coating agents of the present invention provide better adhesion of the composition to the bladder wall. Consequently, the composition and, in particular, the EO9 contacts and may be able to penetrate the avascular tissue that comprises for a time sufficient to treat the bladder cancer. In one embodiment of the present invention, the coating agent is propylene glycol. In other exemplary embodiments of the present invention, the coating agent can be selected from the group consisting of hydroxypropylcellulose, carboxymethylcellulose, chitosan hydrochloride, lectin, or polycarbophil.
  • [0013]
    In yet another embodiment of the present invention, the compositions of the present invention can be delivered to the bladder wall by a liposome. According to one embodiment of the present invention, the liposomes used are unilamellar or multilamellar and contain at least one cationic phospholipid such as stearylamine, 1,2-diacyl-3-trimethylammonium-propane (TAP) or 1,2-triacyl-3-dimethylammonium-propane (DAP). In another embodiment of the present invention, the surface liposomes may be coated with polyethylene glycol to prolong the circulating half-life of the liposomes. In yet another embodiment of the present invention, neutrally charged liposomes such as, but not limited to, phosphatidylcholine and cholesterol can also be used for liposomal entrapment of the compositions of the present invention. In another embodiment, the compositions of the present invention can be delivered to the bladder wall by a microsphere such as those known or developed in the art.
  • [0014]
    In yet another embodiment, the compositions of the present invention can be delivered to a patient intravenously. The lyophilized composition of the present invention can be reconstituted using the formulation vehicles of the present invention. The reconstituted composition can then be diluted to a desired concentration and delivered to a patient intravenously.
  • [0015]
    The following experiments were conducted to determine the activity of NQ01 in a series of human bladder tumors and normal bladder tissue by both enzymatic and immunohistochemical techniques. Furthermore, the following experiments evaluate strategies for reducing possible system toxicity arising from intravesical therapy based upon the fact that the aerobic activity of EO9 against cell lines is enhanced under mild acidic conditions (Phillips et al., 1992). Administration of EO9 in an acidic vehicle would result in greater activity within the bladder and any drug absorbed into the blood stream would become relatively inactive due to the rise in extracellular pH. The following experiments also determine the role of NQ01 in the activation of EO9 under acidic conditions.
  • [0016]
    Collection of tumor and normal bladder specimens. Ethical approval for tissue collection was obtained from the Local Research Ethical Committee (Bradford NHS Trust) and samples taken from patients following informed consent. A total of 17 paired cold pinch biopsies were taken from bladder tumors and macroscopically normal looking bladder mucosa at cystoscopy, immediately prior to formal transurethral resection of the tumor. Three specimens were taken from patients undergoing cystectomy and tumor and normal samples dissected by pathologists within one hour of surgical removal. Specimens were flash frozen in liquid nitrogen and transported for NQOI enzyme analysis. Further biopsies were taken of the normal bladder mucosa immediately adjacent to the previous biopsy site and sent at the end of the procedure, along with the resected tumor, in formalin for routine histological analysis. In this way bladder tumor and normal bladder urothelium enzymology could be directly correlated with the appropriate tissue histology in each patient. Immunohistochemistry was performed from the subsequently archived wax blocks prepared for histology.
  • [0017]
    Biochemical determination of NQOI activity. Cell cultures in exponential growth were trypsinised, washed twice with Hanks balanced salt solution (HBSS) and sonicated on ice (3×30 sec bursts at 40% duty cycle and output setting 4 on a Semat 250 cell sonicator). NQO1 activity and protein concentration was determined as described below. Tissues were homogenised (10% w/v homogenate) in sucrose (0.25M) using a Iml tissue homogeniser (Fisher Scientific). Cytosolic fractions were prepared by centrifugation of the homogenate at 18,000 g for 4 min followed by further centrifugation of the supernatant at 110,000 g for 1 h at 4° C. in a Beckman Optima TL ultracentrifuge. Activity of NQO1 in the supernatant was determined spectrophotometrically (Beckman DU650 spectrophotometer) by measuring the dicumarol sensitive reduction of dichlorophenolindophenol (DCPIP, Sigma Aldrich, UK) at 600 nm (Traver et al, 1992). This assay has been extensively validated for use in measuring NQO1 activity in both tissue and cell homogenates and has been shown to be preferable to other assays for NQO1 activity (Hodnick and Sartorelli, 1997). Each reaction contained NADH (200 IzM), DCPIP (40/iM, Sigma Aldrich, UK), Dicumarol (20 uM, when required, Sigma Aldrich, UK), cytosolic fraction of tissues (50 pl per assay) in a final volume of 1 ml Tris HCl buffer (50 mM, pH 7.4) containing bovine serum albumin (0.7 mg ml−1, Sigma Aldrich, UK). Rates of DCPIP reduction were calculated from the initial linear part of the reaction curve (30s) and results were expressed in terms of nmol DCPIP reduced /min/mg protein using a molar extinction coefficient of 21 mNT′ cm−1 for DCPIP. Protein concentration was determined using the Bradford assay (Bradford, 1976).
  • [0018]
    Immunohistochemistry. Polyclonal antibodies (raised in rabbits) to purified rat NQO1 were a gift from Professor Richard Knox (Enact Pharma Plc). Validation of the antibody for use in immunohistochemistry studies was performed by Western blot analysis using both purified human recombinant NQO1 and cell extracts derived from a panel of cell lines of human origin. These cell lines included H460 (human NSCLC), RT112 (human bladder carcinoma), HT-29 (human colon carcinoma), BE (human colon carcinoma), MT1 (human breast) and DLD-1 (human colon carcinoma). The BE cell line has been genotyped for the C609T polymorphic variant of NQOI and is a homozygous mutant (and therefore devoid of NQO1 enzyme activity) with respect to this polymorphism (Traver et al, 1992). Cells were washed in ice cold phosphate buffered saline and lysed by sonication (30 seconds on ice) in Tris HCl (50 mM, pH 7.5) containing 2 mM EGTA, 2 mM PMSF and 25 Ftg ml−1 leupeptin. Protein concentration was estimated using the Bradford assay (Bradford, 1976) and a total of 12.5 ug of protein (in Lamelli sample loading buffer) applied to a 12% SDS-PAGE gel. Following electrophoretic transfer to nitrocellulose paper, membranes were blocked in TBS/Tween 20 (0.1%) containing 5% non-fat dry milk for 1 h at room temperature. Membranes were washed in TBS/Tween 20 (0.1%) prior to the addition of rabbit anti-rat NQO1 antibody (1:100 dilution) and incubated at room temperature for I h. Membranes were extensively washed in TBS/Tween 20 (0.1%) followed by the addition of anti-rabbit IgG horseraddish peroxidase conjugated secondary antibody (1:5000 dilution in TBS/Tween 20). Proteins were visualised by ECL based chemiluminescence as described by the manufacturer (Amersham Pharmacia Biotech, Bucks, UK).
  • [0019]
    For immunohistochemical studies, all tissues (both tumor and normal bladder mucosa) were fixed in 10% formalin, processed routinely and embedded in paraffin wax. Two sections of each tissue block were placed on one slide, one section served as the test and the other as a negative control (no primary antibody). A total of 5 sections from each sample were stained for NQ01 (plus negative controls) and tumor and normal samples from a total of 17 patients were analysed. Sections (5 um) were dewaxed, rehydrated and incubated with primary antibody (1:400 dilution) for 4 hours. Sections were then washed and incubated with biotinylated mouse anti rabbit IgG for 30 min prior to immunoperoxidase staining using VECTASTAIN ABC reagents and DAB (Vector Laboratories Ltd, Peterborough, UK). Sections were counterstained with haematoxylin according to standard procedures.
  • [0020]
    Cell culture and chemosensitivity studies. E09 was a gift from NDDO Oncology, Amsterdam and MMC was obtained from the Department of Pharmacy, St Lukes Hospital, Bradford. H460 (human NSCLC) cell line was obtained from the American Type Culture Collection (ATCC). HT-29 (human colon carcinoma), RT112/83 (human bladder carcinoma epithelial), EJ138 (human bladder carcinoma) and T24/83 (human bladder transitional cell carcinoma) cell lines were obtained from the European Collection of Animal Cell Cultures (ECACC). A2780 (human ovarian carcinoma) and BE (human colon carcinoma) cells were gifts from Dr T Ward (Paterson Institute, Manchester, UK). All cell lines were maintained as monolayer cultures in RPNII 1640 culture medium supplemented with fetal calf serum (10%), sodium pyruvate (2 mM), L-glutamine (2 mM), penicillin/streptomycin (50 IU/ml/50 jug/ml) and buffered with HEPES (25 mK. All cell culture materials were purchased from Gibco BRL (Paisley, UK). Cells were exposed to MMC or E09 at a range of doses for one hour and chemosensitivity was assessed following a five day recovery period using the MTT assay, details of which have been described elsewhere (Phillips et al, 1992). The pH of the medium used during drug exposure was adjusted using small aliquots of concentrated HCl (40 A conc HCl [10.5M] to 20 ml medium gives a pH of 6.0). Calibration curves were conducted over a broad range of pH values in culture medium (pH 3.5 to 11) and the stability of the pH conditions monitored over a one hour incubation period at 37° C. At all pH values, no significant changes in the pH of the medium was observed over the one hour drug exposure period (data not presented).
  • [0021]
    HT-29 multicell spheroids were prepared by seeding 5×105 cells into T25 flasks which had been based coated with agar (1% w/v) and incubated for 24 h at 37° C. Immature spheroids were then transferred to a spinner flask (Techne) containing 250 m1 of RPMI 1640 growth medium and spheroids were kept in suspension by stirring at 50 rpm. When spheroids reached a diameter of approximately 500 Am, they were harvested for chemosensitivity studies. Multicell spheroids were exposed to a range of E09 concentrations at pHe 6.0 and 7.4 for one hour at 37° C. Following drug incubation, spheroids were washed twice in HBSS prior to dissagregation into single cells using trypsin EDTA. Disaggregated spheroids were then washed in HBSS and then plated into 96 well plates (1×103 cells per well). and incubated at 37° C. for four days. Chemosensitivity was assessed using the NM assay as described elsewhere (Phillips et al, 1992).
  • [0022]
    The role of NQ01 in the activation of E09 at pHe values of 7.4 and 6.0 was evaluated using the NQO1 inhibitor Flavone Acetic Acid (FAA), details of which are described elsewhere (Phillips, 1999). FAA is a competetive inhibitor of NQ01 with respect to NADH and at a final concentration of 2 mM, inhibition of NQO1 is >95% whereas the activity of cytochrome P450 reductase and cytochrome b5 reductase is not substantially altered (<5% inhibition). Briefly, H460 cells (NQO1 rich) were plated into 96 well plates at a density of 2×103 cells per well. Following an overnight incubation at 37° C., medium was replaced with fresh medium (pH 7.4) containing a non-toxic concentration of FAA (2 mM) and incubated for one hour at 37° C. Medium was then replaced with fresh medium containing E09 (range of drug concentrations) and FAA (2 mM) at either pHe 7.4 or 6.0. Following a further one hour incubation at 37° C., cells were washed twice with HBSS and incubated at 37° C. in growth medium for five days. Chemosensitivity was determined by the NM assay as described above and results were expressed in terms of IC50 values, selectivity ratios (ICSo at pHe 7.4 IC50 at pHe 6.0) and protection ratios (ICSO FAA/E09 combinations/IC50 for E09 alone).
  • [0023]
    Substrate specificity. The influence of acidic pHe on substrate specificity for purified human NQ01 was determined as described previously (Phillips 1996, Walton et al, 1991). NQ01 mediated reduction of the quinone to the hydroquinone species is difficult to detect by conventional assays thereby necessitating the use of a reporter signal generating step. In this assay, the hydroquinone acts as an intermediate electron acceptor which subsequently reduces cytochrome c which can readily be detected spectrophotometrically. Recombinant human NQ01 was derived from E.coli transformed with the pKK233-2 expression plasimd containing the full length cDNA sequence for human NQ01 isolated from the (Beall et al, 1994). Following IPTG induction, NQO1 was purified by cybacron blue affinity chromatography, details of which are described elsewhere (Phillips, 1996). The purified protein had a molecular weight of approximately 31 kDa and a specific activity of 139/Amol DCPIP reduced/min/mg protein (Phillips, 1996). Reduction of E09 by recombinant human NQO1 was determined at pH 6.0 and 7.4 by measuring the rate of reduction of cytochrome c was measured at 550 nm on a Beckman DU 650 spectrophotometer according to previously published methods (Phillips, 1996). Results were expressed in terms of umol cytochrome c reduced/min/mg protein using a molar extinction coefficient of 21.1 mM−1 cm−1 for cytochrome c.
  • [0024]
    Measurement of intracellular pH. Intracellular pH was determined using the fluorescent pH indicator BCECF (2,7-bis-(2-carboxy-ethyl)-5-(and-6) carboxyfluorescein (Molecular Probes, Eugene, USA) according to manufacturers instructions. Confluent flasks of cells were washed with HBSS to remove any traces of serum containing RPMI medium and then incubated with the esterified form of BCECF (BCECF-AM) at a concentration of 2 [tM in HBSS for one hour at 37° C. The non-denaturing detergent Pluronic was added to the probe to aid dispersion. Cells were then washed to remove all traces of BCECF-AM and then trypsinized before being suspended in serum-free/phenol red-free RPM1 medium (Gibco BRL, Paisley, UK) at a concentration of 106 cells per ml at pH 6 for one hour. Flourescence measurement was determined in a Perkin-Elmer fluorescence spectrophotometer in UV grade disposable 4 ml cuvettes (Fischer Scientific) with excitation wavelengths 500 nm and 450 nm (excitation bandpass slit of 10 nm) and emission wavelength fixed at 530 nm (emission bandpass slit of 2.5 nm). These were determined to be optimal settings for the machine and system under study. An in-situ calibration was performed for every pHi determination with a range of six pH's from 4 to 9 using the ionophore nigericin at a concentration of 22.8 p,M to equilibrate pHe with pHi . Calculation of the ratio of fluorescence at 500 nm/450 nm was calculated after subtraction of background fluorescence from blanks at each pH (serum free, phenol red free RPMI without cells).
  • [0025]
    Activity of NQO1 in tumor and normal bladder specimens. The biochemical activity of NQO1 in paired samples of tumor (grade/stage ranging from G2 pTa to G2/G3 T4) and normal bladder mucosa (with three cystectomy specimens) taken from a series of 20 patients is presented in table 1. Within the tumor specimens, a broad range of NQO1 activity existed ranging from 571.4 nmoUmin/mg to undetectable (<0.1 nmol/min/mg). In histologically nonnal bladder mucosa specimens, NQO1 activity ranged from 190.9 to <0.1 nmoUmin/mg. In the majority of patients NQO1 activity in the tumor was greater than in the normal bladder mucosa. Tumor grade and stage did not correlate with NQO1 activity (table 1).
  • [0026]
    Validation of NQO1 antibody and inununohistochemical localization of NQO1. Western blot analysis demonstrates that polyclonal anti rat NQO1 antibody cross reacts with human NQO1 with a single band at approximately 31 kDa observed for both cell extracts and purified human NQO1. Titration of purified NQO 1 results in a decrease in band intensity and in cell extracts, band intensity was qualitatively consistent with NQO1 enzyme activity. In addition, the antibody does not detect NQO1 in the BE cell line which is devoid of NQ01 activity as a result of the C609T polymorphism. No non-specific bands were observed on Western blots. Superficial and invasive tumors with high to intermediate levels of NQO1 as determined by biochemical assays (patient numbers 1, 4 and 5 in table 1) clearly stained positive for NQO1. Staining was confined to the cytoplasm of tumor cells with little or no staining of stromal cells.
  • [0027]
    In other tumors with intermediate or low levels of NQOI activity, staining was heterogeneous with pockets of cells containing high levels of NQ01 protein. Normal bladder wall sections were obtained from a patient who underwent cystectomy (G3pT4 bladder tumor), ureter and urethra were obtained from another patient who underwent cystectomy (G3 pT3a bladder tumor). In the bladder wall, no NQO1 staining was observed in the urothelium although slight staining was present in smooth muscle layers. The urethra was negative although cells on the luminal surface of the ureter were positively stained. The basal layers of the ureter lining were however negatively stained. No evidence of invasive malignancy or in situ carcinoma were observed in the ureter and urethra or in the section of bladder wall presented. In 16 other normal bladder biopsy and cystectomy specimens, no positive staining of the urothelium was observed.
  • [0028]
    Influence of pH on substrate specificity and chemosensitivity. The ability of E09 to serve as a substrate for NQO1 was not influenced by pH with specific activities of 21.10±2.3 and 21.30±1.5 pmol cytochrome c reduced/min/mg protein at pH 7.4 and 6.0 respectively. The response of a panel of cell lines with a range of NQO1 activity (<1.0 to 1,898±276 nmol/min/mg) to E09 and MMC at pHe values of 7.4 and 6.0 is presented in table 2. At pHe=7.4, a good correlation existed between NQ01 activity and chemosensitivity to E09. In the case of MMC (table 2), a relationship between NQ01 and chemosensitivity was apparent (at pHe 7.4) although this relationship was not as prominent as shown by E09 with a narrow range of IC50 values (range 0.9 to 7.0 ttM) observed in cell lines which cover a broad range of NQ01 activity (ranging from <1.0 to 1,898 nmol/min/mg). Both MMC and E09 are preferentially more toxic to cells at pHe values of 6.0 although much greater potentiation of E09 activity is seen with SR values (SR=selectivity ratio defined as IC50 pHe 7.4/IC50 pHe 6.0) ranging from 3.92 to 17.21 for E09 compared with 1.02 to 4.50 for MMC (table 2). The activity of E09 was enhanced in both NQO1 rich and deficient cell lines when pHe was reduced to 6.0 and the relationship between NQO1 and chemosensitivity remained good when cells were exposed to E09 under acidic conditions. No cell kill was observed in control cultures when the pHe was decreased to 6.0 (in the absence of drug) as determined by the MTT assay. The response of H460 cells to E09 at pHe values of 7.4 and 6.0 in the presence and absence of FAA (2 mM) is presented in table 3. At both pHe values, the response of H460 cells to E09 was reduced in the presence of FAA. Protection ratios defined as the IC50 for E09 plus FAA divided by the IC50 value for E09 alone were similar for cells under acidic and physiological pHe values (14.63 and 13.95 respectively, table 3). Selectivity ratios defined as the IC50 at pHe 7.4 divided by the IC50 at pHe 6.0 in the presence and absence of FAA were also similar with SR values of 6.31 and 6.02 for E09 alone and E09 plus FAA respectively (table 3). The response of HT-29 multicell spheroids to E09 demonstrate that spheroids exposed to E09 at pHe 6.0 were significantly more responsive than at pHe 7.4 with IC50 values of 9.89±0.89 and 24.24±3.29 AM respectively. Spheroids were significantly less responsive to E09 than the same cells exposed to E09 as monolayers at both pHe values with ratios of IC50 values for spheroids to monolayers of 202 and 341 at pHe values of 7.4 and 6.0 respectively.
  • [0029]
    Influence of acidic pHe conditions on pHi. PM values following a one hour incubation at pHe 6.0 were 6.44±0.04, 6.51±0.02 and 6.42±0.05 in A549, RT112/83 and A2780 cells respectively. Addition of the ionophore nigericin (after a one hour incubation at pHe 6.0) resulted in the equilibration of pHe and p11i.
  • [0030]
    In terms of bioreductive drug development, two of the critical factors which will ultimately determine selectivity are the enzymology of tumors and the presence of hypoxia (Workman, 1994). As outlined in the introduction, the presence or absence of NQ01 is central to the design of appropriate E09 based therapeutic strategies aimed at targeting either the aerobic (NQO1 rich cells) or hypoxic fraction (NQO1 deficient tumors) of tumors. Workman (1994) has outlined a proposed mechanism for the different properties of E09 under aerobic and hypoxic conditions based on the hypothesis that it is the semiquinone (product of one electron reduction) rather than the hydroquinone which is responsible for toxicity. In NQO1 deficient cells, the semiquinone produced as a result of one electron reductases would be relatively non-toxic as it would rapidly redox cycle back to the parent compound. Free radical species generated as a result of redox cycling would be detoxified by superoxide dismutase or catalase but under hypoxic conditions, the semiquinone would be relatively stable. If this were the major toxic species, then the activity of E09 against cells with low NQO1 would be potentiated. In NQO1 rich cells however, the major product formed would be the hydroquinone. Aerobic toxicity could be generated as a result of the back oxidation of the hydroquinone to the semiquinone species or the parent quinone (Butler et al, 1996) resulting is free radical generation. Under hypoxic conditions however the hydroquinone will be more stable and if this is relatively nontoxic, then the activity of E09 against NQO1 cells under hypoxia would not be potentiated. Whilst the mechanism of action of E09 under aerobic and hypoxic conditions is complex, the biological data suggest that E09 should target the aerobic fraction of NQO1 rich tumors or the hypoxic fraction of NQO1 deficient tumors (Workman, 1994).
  • [0031]
    Analysis of NQ01 activity in tumor and normal bladder tissues has clearly identified patients whose tumors are either NQO1 rich or NQO1 deficient (table 1). Within the subset of NQ01 rich tumors, enzyme activity is elevated relative to the normal bladder urothelium. Immunohistochemical studies confirm these biochemical measurements with staining confined to tumor cells as opposed to normal stromal cells. Within normal bladder tissues, NQ01 staining was absent from the urothelial lining of the bladder and the urethra. Faint staining of the superficial layers of the ureter was observed although the underlying basal layers of the ureter were negatively stained. Similarly, faint staining of the smooth muscle layers of the bladder, ureter and urethra were also observed. These studies suggest that a proportion of patients with bladder tumors (at various grades and stages of the disease) exhibit a significant differential in terms of NQO1 activity which could potentially be exploited by E09 based therapies directed against the aerobic fraction of tumor cells. With regards to the ability of E09 to selectively kill hypoxic NQ01 deficient cells, a subset of patients also exist whose tumors are devoid of NQ01 activity (table 1). It is not known whether or not bladder tumors contain regions of low oxygen tension and further studies are required using hypoxia markers such as pimonidazole (Kennedy et al, 1997) to address this issue and to establish the relationship between NQ01 activity and hypoxia in tumors.
  • [0032]
    Whilst biochemical and immunohistochemical studies demonstrate that a subset of patients exist which have the appropriate tumor enzymology to activate E09 (under aerobic conditions), intravesical chemotherapy can result in systemic toxicity due to the drug entering the blood supply. This study has also evaluated a potential strategy for minimizing any risk of systemic toxicity based upon the hypothesis that administration of E09 in an acidic vehicle would enhance the potency of E09 (Phillips et al, 1992) within the bladder and that any drug reaching the blood stream would become relatively inactive due to a rise in pHe. Selectivity for aerobic cells would still be determined by NQO1 activity and therefore it is essential to determine the role that NQO1 plays in the activation of E09 under acidic pHe conditions. In a panel of cell lines with a broad spectrum of NQO1 activity, reducing the pHe to 6.0 enhances the potency of E09 under aerobic conditions in all cases (with SR values ranging from 3.92 to 17.21, table 2). In the case of MMC, potency is also enhanced at low pHe values although the magnitude of the pH dependent increase in toxicity is reduced (SR values ranging from 1.02 to 4.50, table 2) compared with E09. With respect to MMC, one explanation for increased activity under acidic conditions has been attributed to the fact that MMC becomes a substrate for NQO1 under acidic conditions (Pan et al, 1993, Siegel et al, 1993). This is not the case with E09 as rates of reduction of E09 by purified human NQO1 are not influenced by pH (21.10±2.30 and 21.30±1.50 limol cytochrome c reduced/min/mg protein at pH 7.4 and 6.0 respectively). Recent studies have demonstrated that the activity of E09 is enhanced under acidic conditions (pHe=6.5) but only when the intracellular pH is reduced (pIIi=6.5) by co-incubation with nigericin (Kuin et al, 1999). The results of this study are in agreement with this finding as pHi becomes acidic (pHi values range from 6.42±0.05 to 6.51±0.02 depending on the cell line) when cells are cultured under pHe 6.0 conditions.
  • [0033]
    In the panel of cell lines used in this study, a good correlation exists between NQO1 activity and chemosensitivity at both pHe values of 7.4 and 6.0. A strong relationship between NQO1 activity and response under aerobic conditions (at pHe 7.4) has been established previously by several groups (Robertson et al, 1994, Fitzsimmons et al, 1996, Smitkamp-Wilms et al, 1994) and there is clear evidence that NQ01 plays a central role in the mechanism of action of E09 under aerobic conditions (Workman, 1994). The good correlation between NQ01 activity and response at pHe 6.0, in conjunction with the fact that E09 is still a good substrate for NQ01 at pH 6.0, suggests that NQO1 plays a significant role in E09's mechanism of action at acidic pHe values under aerobic conditions. It is of interest to note however that the activity of E09 against BE cells (which are devoid of NQ01 activity as a result of the C609T polymorphism, Traver et al, 1992) is also enhanced under acidic pHe conditions (table 2). This suggests that there is a NQO1 independent mechanism for the increased activity of E09 under acidic conditions. This is confirmed by the use of the NQ01 inhibitor FAA where the ‘protection ratios’ (defined as the ratio of IC50 values for E09 plus FAA divided by the ICSo values for E09) are similar at both pHe 7.4 and 6.0 (13.95 and 14.63 respectively, table 3). If NQO1 played a central role in the activation of E09 at pHe 6.0, then the protection ratio at pHe 6.0 would be significantly greater than the protection ratio at pHe 7.4. The mechanism behind the NQ01 independent activation of E09 is unclear although it is a well known fact that the reactivity of aziridine ring structures is enhanced by protonation resulting in ring opening to the aziridinium ion which is a potent alkylating species (Mossoba et al, 1985, Gutierrez, 1989). Alternatively, E09 is a substrate for other one electron reductases (Maliepaard et al, 1995, Saunders et al, 2000) and further studies designed to evaluate whether E09's metabolism by these enzymes is pH dependent needs to be determined. The potency of E09 can be enhanced further by reducing pHe below 6.0 (Phillips et al, 1992) but these conditions are unlikely to provide significant clinical benefits as E09 becomes progressively more unstable when pH is reduced to 5.5 (t′/s=37 min). From a pharmacological standpoint, administration of E09 in a vehicle at pH 6.0 would appear desirable. Not only would this result in significant enhancement of E09 activity but also the stability of E09 would be sufficient (tlh=2.5 h) to maintain drug exposure parameters at a therapeutic level.
  • [0034]
    With regards to the activity of E09 against three dimensional culture models in vitro, this study has demonstrated that reducing the pHe to 6.0 enhances the potency of E09 against multicell spheroids although the magnitude of this effect is reduced compared with monolayer cultures. It is not known whether or not reduction in pHe results in greater cell kill throughout the spheroid or if it is confined to the surface of the spheroid exposed to medium. In comparison with MMC, previous studies using histocultures exposed to MMC demonstrated that no difference in toxicity exists between physiological and acidic pHe conditions (Yen et al, 1996). The pH dependent increase in E09 toxicity against spheroids suggests that manipulation of pHe may not only be of use in treating a multilayered solid bladder tumor but may offer an advantage over MMC. It should however be stated that multicell spheroids are significantly less responsive to E09 than mono] ayers, presumably because of the poor penetration properties of E09 through avascular tissue (Phillips et al, 1998). E09 can nevertheless kill >90% of cells in spheroids suggesting that a higher doses at least, the penetration of E09 is sufficient to eradicate cells which reside some distance away from the surface of the spheroid.
  • [0035]
    In conclusion, the results of this study have demonstrated that within a population of patients with bladder tumors at various stages and grades of the disease, there exists a great heterogeneity regarding the expression of NQO1. The majority of patients have tumors possessing elevated levels of NQO 1 while a small subset of patients appear to be devoid of NQO1 activity. The heterogeneous nature of NQO1 activity described here is consistent with several other studies in various tumor types (Malkinson et al, 1992, Smitkamp-Wilms et al, 1995, Siegel et al, 1998). These findings reinforce the view that ‘enzyme profiling’ of individual patients could be valuable prior to therapeutic intervention with bioreductive drugs (Workman, 1994). This is to our knowledge the first study to characterize NQO1 activity and cellular localization in bladder tumors and provide strong evidence to support the evaluation of E09 against superficial and locally invasive bladder tumors. This study has clearly demonstrated that under aerobic conditions, E09 is much more potent under acid conditions (pH6.0) than at physiological pH (pH7.4). The mechanism for this increased E09 potency appears to be NQ01 independent and whilst this will not improve (or reduce) selectivity, it may prove beneficial in terms of reducing the therapeutically effective dose of E09. Dose reduction in conjunction with the fact that a reduction in the potency of E09 due to the increased pHe in the blood stream suggests that systemic toxicity arising from the intravesical administration of E09 would be low. In addition, this study shows that under physiological conditions the activity of E09 is much lower in tissues with “normal” expression of NQO1 compared to “high” NQO1 expressing tissues (i.e. the tumors). The results of this study provide strong evidence in support of the proposal that intravesical administration of E09 may have activity against bladder tumors.
  • REFERENCES
  • [0036]
    Butler J, Spanswick V J and Cummings J (1996) The autooxidation of reduced forms of E09. Free Rad Res 25: 141-148.
  • [0037]
    Bradford M M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254.
  • [0038]
    Connors T A (1996) Bioreductive agents, hypoxic cells and therapy. Eur J Cancer 32A: 1833-1834.
  • [0039]
    Cummings J, Spanswick V J, Tomaz M and Smyth J F (1998a) Enzymology of MMC metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development. Biochem Pharmacol 56: 405-414.
  • [0040]
    Cummings J, Spanswick V J, Gardiner J, Ritchie A and Smyth, I F (1998b) Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone E09. Biochem Pharmacol 55: 253-260.
  • [0041]
    Dirix L Y, Tonnesen F, Cassidy J, Epelbaum R, Huinink W W T, Pavlidis N, Sorio R, Gamucci T, Wolff I, Tevelde A, Lan J, and Verweij J (1996) E09 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the early clinical studies group. Eur J Cancer 32A: 2019-2022.
  • [0042]
    Fitzsimmons S A, Workman P, Grever M, Paull K, Camalier R and Lewis A D (1996) Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to MMC and E09. J Natl Cancer Inst 88: 259-269 Gutierrez P L (1989) Mechanism of bioreductive alkylation. The example of diazaquinone (AZQ. Free Radical Bio Med 6: 405-445.
  • [0043]
    Hendriks H R, Piazo P E, Berger D P, Kooistra K L, Bibby M C, Boven E, Dreef-Van Der Meulen H C, Henrar-REC, Fiebig H H, Double J A, Hornstra H W, Pinedo H M, Workman P and Swartsmann G (1993) E09: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906.
  • [0044]
    Herr H W (1987) Intravesical therapy—a critical review. Urology Clinics of N America 14: 399-404.
  • [0045]
    Hodnick W F and Sartorelli A C (1997) Measurement of dicumarol sensitive NADPH: (menadione cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates. Anal Biochem 252: 165-168.
  • [0046]
    Kennedy A S, Raleigh J A, Perez G M, Calkins D P, Thrall D E, Novotny D B, Varia M A (1997) Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37: 897-905.
  • [0047]
    Kuin A, Alders M, Lamfers M, Van Zuidam D J, Essers M, Beijnen J H and Smets L A (1999) Potentiation of anti-cancer activity at low intratumoural pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br J Cancer 79: 793-801.
  • [0048]
    Maffezzini M, Simonata A, Zanon M, Raber M and Carmig ani G (1996) Up-front chemotherapy for low stage low grade recurrent bladder cancer. J Urol 155: 91-93. Malkinson A M, Siegel D, Forrest G L, Gazdar A F, Oie H K, Chan D C, Bunn P A, Mabry M, Dykes D J, Harrison S D and Ross D (1992) Elevated NQO1 activity and messenger RNA content in human non small cell lung carcinoma—Relationship to the response of lung tumor xenografts to MMC. Cancer Res 52: 4752-4757.
  • [0049]
    Maliepaard M, Wolf A, Groot S E, De Mol N J and Janssen L H M (1995) Indoloquinone E09: DNA interstrand cross linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 71: 836-839.
  • [0050]
    Mossoba M M, Alizadeh M and Gutierrez P L (1985) Mechanism for the reductive activation of diazaquinone. J Pharm Sci 74: 1249-1254.
  • [0051]
    Newling D (1990) Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group. Br J Cancer61: 497-499.
  • [0052]
    Oosterlink W, Kurth K H, Schr6der F, Bultinck J, Hammond B, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer Genitourinary Group (1993) A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomised trial comparing transurethral resection followed by a single instillation of epirubicin or water in single stage Ta, T 1 papillary carcinoma of the bladder. J Urol 149: 749-752.
  • [0053]
    Pan S S, Yu F and Hipsher C (1993) Enzymatic and pH modulation of MMC induced DNA damage in MMC resistant HCT 116 human colon cancer cells. Mol Pharmacol 43: 870-877.
  • [0054]
    Phillips R M, Hulbert P B, Bibby M C, Sleigh N R, and Double J A (1992) In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 65: 359-364.
  • [0055]
    Phillips R M (1996) Bioreductive activation of a series of analogues of 5-aziridinyl-3hydroxymethyl-l-methyl-2-[1H-indolo-4,7-dione] prop-(3-en-a-ol (E09) by human NQO1. Biochem Pharmacol 52: 1711-1718.
  • [0056]
    Phillips R M, Loadman P M and Cronin B P (1998) Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumors. Br J Cancer 77: 2112-2119.
  • [0057]
    Phillips R M (1999) Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DNIXAA) and flavone-8acetic acid (FAA): Implications for bioreductive drug development. Biochem Pharmacol 58: 303-310.
  • [0058]
    Plumb J A and Workman P (1994) Unusually marked hypoxic sensitisation to indoloquinone E09 and MMC in a human colon tumor cell line that lacks NQOI activity. Int J Cancer 56: 134-139.
  • [0059]
    Robertson N, Haigh A, Adams G E and Stratford U (1994) Factors affecting sensitivity to E09 in rodent and human tumor cells in vitro: NQ01 activity and hypoxia. Eur J Cancer 30A: 1013-1019.
  • [0060]
    Saunders M P, Jaffar M, Patterson A V, Nolan J, Naylor M A, Phillips R M, Harris A L and Stratford H (2000) The relative importance of NADPH:cytochrome c (P450) reductase for determining the sensitivity of human tumor cells to the indoloquinone E09 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 59: 993-996.
  • [0061]
    Schellens J H M, Planting A S T, Van Acker B A C, Loos W J, De Boer-Dennert M, Van Der Burg M E L, Koier I, Krediet R T, Stoter G and Verweij J (1994) Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 86: 906-912.
  • [0062]
    Schlager J J and Powis G (1988) MMC is not metabolised by but is an inhibitor of human kidney NAD(P)H:(quinone acceptor) oxidoreductase. Cancer Chemother Pharmacol 22: 126-130.
  • [0063]
    Siegel D, Gibson N W, Preusch P C and Ross D (1990) Metabolism of MMC by NQ01: Role in MMC induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-7489.
  • [0064]
    Siegel D, Beall H D, Kasai M, Gibson N W and Ross D (1993) PH dependent inactivation of NQ01 by MMC and porfiromycin. Mol Pharmacol 44: 1128-1134. Siegel D, Franklin W A and Ross D (1998) Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4: 2065-2070.
  • [0065]
    Smitkamp-Wilms E, Peters G J, Pinedo H M, Van Arkotte J and Giaccone G (1994) Chemosensitivity to the indoloquinone E09 is correlated with NQ01 activity and gene expression. Biochem Pharmacol 47: 1325-1332.
  • [0066]
    Smitskamp-Wilms E, Giaccone G, Pinedo H M, Van Der Laan B F A M and Peters G J (1995) NQ01 activity in normal and neoplastic human tissues: An indicator of sensitivity to bioreductive agents?. Br J Cancer 72: 917-921.
  • [0067]
    Tolley D A, Parmar M K B, Grigor K M, Lallemand G and the Medical Research Council superficial bladder cancer working party (1996) The effect of intravesical
  • [0068]
    MMC on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup. J Urol 155: 1233-1238.
  • [0069]
    Traver R D, Horikoshi T, Dannenberg K D, Stadlbauer T H W, Dannenberg P V, Ross D and Gibson N W (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterisation of a mutation which modulates NQ01 activity and mitomycin sensitivity. Cancer Res 52: 797-802.
  • [0070]
    Walton M I, Smith P J and Workman P (1991) The role of NAD(P)H:quinone reductase (EC 1.6.99.2, NQO1) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. Cancer Commun 3: 199-206.
  • [0071]
    Workman P (1994) Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer drugs and quinone metabolising enzymes, particularly NQO1. Oncol Res 6: 461-475.
  • [0072]
    Yen W C, Schmittgen T and Au J L (1996) Different pH dependency of mitomycin C activity in monolayer and three dimensional cultures. Pharmaceut Res 13: 1887-1891.
    TABLE 1
    Tumor histology reports and NQO1 activity in paired samples of bladder
    tumor and normal bladder mucosa.
    Ratio of
    NQO1 Activity NQO1 Activity NQO1 levels
    Patient Tumor Tumor Normal in tumor to
    No. histology (nmol/min/mg) (nmol/min/mg) normal tissue.
    1f,s,i,p G2 pTa 571.4 <0.1 571.
    2m,s,r G3 pT2 273.3 <0.1 273.
    3f,s,i G1pTa 107.80 <0.1 107.
    4m,e,i G3 pT2/3 73.36 <0.1 73.3
    5m,s,i G3pT4(0′ 81.30 4.10 19.8
    6h G2PT1 309.50 25.20 12.1
    7m,n,r,o G3 pT2 10.00 <0.1 10.0
    8f n,i G3pT2 9.80 <0.1 9.80
    9m,n,i G2 pT2 4.40 <0.1 4.40
    10m,s,c G3 pT2 34.01 8.50 4.00
    11m,s G1 pTa 69.76 22.20 3.14
    12,,n G1pTa 42.16 15.30 2.73
    13m,n,i G3 pT2 179.6 72.12 2.49
    14m,e,i G2/G3 89.70 63.30 1.41
    T4(C)
    15m,n,r G3 pT2 0.40 <0.1 0.40
    16m,e,c,o G3 PT3(C) 21.60 61.70 0.35
    l7f n,i G2 PTI 58.40 190.90 0.30
    18m,e,o G2 PTI <0.1 <0.1 0
    19f n,i G2 PT I. <0.1 <0.1 0
    20m,e,c,r G2 pT0 <0.1 <0.1 0

    mMale,

    fFemale,

    sSmoker,

    ′Non-smoker,

    eEx-smoker,

    ° Intravesical chemotherapy prior to specimen collection,

    rRadiotherapy prior to specimen collection,

    ′ First presentation,

    P Previous malignancy other than bladder,

    hNo medical history available,

    o Possible occupational carcinogen exposure (i.e., dye industry worker).

    (C) denotes cystectomy specimens. In all cases, protein levels following preparation of the cytosolic fraction were greater than 0.1 mg/ml.
  • [0073]
    TABLE 2
    The relationship between NQ01 activity and chemosensitivity
    to E09 and MMC under physiological and acidic pHe conditions.
    NQO1 IC50 pHe IC50 pHe
    Cell (nmol/ 7.4 6.0
    line Drug min/mg) (nM) (nM) SR*
    H460 E09 1652 ± 142  60 ± 10 9.5 ± 2  6.31
    HT-29 E09 688 ± 52 120 ± 53  29 ± 10 4.13
    T24/83 E09 285 ± 28 290 ± 65  60 ± 18 4.83
    A2780 E09 159 ± 33 200 ± 50  51 ± 14 3.92
    EJ138 E09  83 ± 14 310 ± 95 39 ± 7 7.94
    RT112 E09 30 ± 3 1050 ± 75   61 ± 13 17.21
    BE E09 <0.1 5300 ± 169 1300 ± 75- 4.07
    H460 MMC 1652 ± 142  900 ± 200  220 ± 130 4.50
    HT-29 MMC 688 ± 52 1050 ± 210  500 ± 240 2.10
    T24/83 MMC 285 ± 28 2150 ± 93  2100 ± 800 1.02
    A2780 MMC 159 ± 33 2400 ± 340 1400 ± 130 1.71
    EJ138 MMC  83 ± 14 1600 ± 200 1400 ± 250 1.14
    RT112 MMC 30 ± 3 3350 ± 250 2000 ± 500 1.67
    BE MMC <0.1 7000 ± 192 4400 ± 215 1.59

    All results presented are the mean of 3 independent experiments (SD values omitted in the interests of presentation).

    *SR (selectivity ratio) = IC5o at pH 7.4/IC5o at pH 6.0
  • [0074]
    TABLE 3
    Response of H460 cells to E09 in the presence or absence
    of FAA (2 mm) at pHe values of 7.4 and 6.0.
    ICso
    Drug pHe (nM) SR* PR**
    E09 7.4 60.0 ± 8.1
    E09 6.0  9.5 ± 2.6 6.31
    E09/FAA 7.4 837 ± 45 13.95
    E09/FAA 6.0- 139 ± 27 6.02 14.63

    *SR = Selectivity Ratio defined as the ratio of ICSo values at pHe = 7.4 divided by the IC50 at pHe = 6.0.

    **Plf = Protection ratio defined as the ratio of IC5o values for E09 plus FAA divided by the IC5o values for E09 alone.

    All values represent the mean ± standard deviation for three independent experiments.
  • [0075]
    TABLE 4
    Neoquin 8 mg/vial lyophilised product
    time (months)
    Storage test item 0 1 2 3 6
     5° C. content* 102.7 ± 1.2  na na 103.8 ± 0.8  100.6 ± 0.6 
    purity**  99.9 ± 0.008 na na 99.5 ± 0.03  99.6 ± 0.03
    residual 6.0% na na 7.0% 6.3%
    moisture***
    pH after 9.5 na na na 9.4
    reconstitution****
    25° C./60% content 102.7 ± 1.2  103.4 ± 0.7  102.1 ± 0.2  102.6 ± 1.3  97.4 ± 1.0
    RH purity  99.9 ± 0.008 99.9 ± 0.05 99.9 ± 0.01 99.2 ± 0.07 98.7 ± 0.2
    residual moisture 6.0% na na 5.9% 5.9%
    pH after 9.5 na na na 9.4
    reconstitution****
    40° C./75% content 102.7 ± 1.2  102.3 ± 1.1  100.4 ± 1.3  101.3 ± 0.2  86.4 ± 2.0
    RH purity  99.9 ± 0.008 99.8 ± 0.01 99.7 ± 0.04 98.4 ± 0.07 97.5 ± 0.2
    residual moisture 6.0% na na 6.2% 6.3%
    pH after 9.5 na na na 9.5
    reconstitution****

    *content as % of labelled content n = 3

    **purity as chromatographic purity n = 3

Claims (11)

  1. 1-4. (canceled)
  2. 5. A medical composition for the intravesical treatment of bladder cancer comprising:
    a) 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09);
    b) propylene glycol;
    c) water; and
    c) sufficient sodium bicarbonate to maintain a pH between 9.0 and 9.5.
  3. 6. The medical composition according to claim 5 further comprising sodium edetate.
  4. 7. The medical composition according to claim 5 wherein said E09 concentration is between 0.0125 mg/mL to 0.4 mg/mL.
  5. 8. The medicament according to claim 5 wherein said propylene glycol is present in a ration of 60 parts to 40 parts of water (v/v).
  6. 9. The medicament according to claim 5 wherein said sodium bicarbonate is present at a concentration of 2% (w/v).
  7. 10. The medical composition according to claim 6 wherein said sodium edentate is present in a concentration pf 0.02% (w/v).
  8. 11. The medical composition according to claim 5 comprising an 8 mg unit dose of E09.
  9. 12. The medical composition according to claims 5 and 6 wherein said, propylene glycol, water, sodium bicarbonate and sodium edentate are present in the ratio of 60/40/2/0.02% v/v/w/w and said E09 is present in a concentration of from 0.0125 mg/mL to 0.4 mg/mL
  10. 13. The medical composition according to claim 11 where in said E09 is present at 0.2 mg/mL.
  11. 14. The medical composition according to claim 11 where in said E09 is present at 0.4 mg/mL.
US11531535 2001-11-01 2006-09-13 Medical Compositions for Intravesical Treatment of Bladder Cancer Abandoned US20070010570A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US34444601 true 2001-11-01 2001-11-01
US10285783 US6894071B2 (en) 2001-11-01 2002-11-01 Medical compositions for intravesical treatment of bladder cancer
US11096566 US20050215615A1 (en) 2001-11-01 2005-04-01 Medical compositions for intravesical treatment of bladder cancer
US11531535 US20070010570A1 (en) 2001-11-01 2006-09-13 Medical Compositions for Intravesical Treatment of Bladder Cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11531535 US20070010570A1 (en) 2001-11-01 2006-09-13 Medical Compositions for Intravesical Treatment of Bladder Cancer
US12053418 US7977369B2 (en) 2001-11-01 2008-03-21 Medical compositions for intravesical treatment of bladder cancer
US12327781 US20090076123A1 (en) 2001-11-01 2008-12-03 Medical Compositions for Intravesical Treatment of Bladder Cancer
US13493911 US8648108B2 (en) 2001-11-01 2012-06-11 Medical compositions for intravesical treatment of bladder cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11096566 Continuation US20050215615A1 (en) 2001-11-01 2005-04-01 Medical compositions for intravesical treatment of bladder cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12053418 Continuation US7977369B2 (en) 2001-11-01 2008-03-21 Medical compositions for intravesical treatment of bladder cancer
US12327781 Continuation US20090076123A1 (en) 2001-11-01 2008-12-03 Medical Compositions for Intravesical Treatment of Bladder Cancer

Publications (1)

Publication Number Publication Date
US20070010570A1 true true US20070010570A1 (en) 2007-01-11

Family

ID=23350584

Family Applications (6)

Application Number Title Priority Date Filing Date
US10285783 Active US6894071B2 (en) 2001-11-01 2002-11-01 Medical compositions for intravesical treatment of bladder cancer
US11096566 Abandoned US20050215615A1 (en) 2001-11-01 2005-04-01 Medical compositions for intravesical treatment of bladder cancer
US11531535 Abandoned US20070010570A1 (en) 2001-11-01 2006-09-13 Medical Compositions for Intravesical Treatment of Bladder Cancer
US12053418 Active 2024-06-26 US7977369B2 (en) 2001-11-01 2008-03-21 Medical compositions for intravesical treatment of bladder cancer
US12327781 Abandoned US20090076123A1 (en) 2001-11-01 2008-12-03 Medical Compositions for Intravesical Treatment of Bladder Cancer
US13493911 Active US8648108B2 (en) 2001-11-01 2012-06-11 Medical compositions for intravesical treatment of bladder cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10285783 Active US6894071B2 (en) 2001-11-01 2002-11-01 Medical compositions for intravesical treatment of bladder cancer
US11096566 Abandoned US20050215615A1 (en) 2001-11-01 2005-04-01 Medical compositions for intravesical treatment of bladder cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12053418 Active 2024-06-26 US7977369B2 (en) 2001-11-01 2008-03-21 Medical compositions for intravesical treatment of bladder cancer
US12327781 Abandoned US20090076123A1 (en) 2001-11-01 2008-12-03 Medical Compositions for Intravesical Treatment of Bladder Cancer
US13493911 Active US8648108B2 (en) 2001-11-01 2012-06-11 Medical compositions for intravesical treatment of bladder cancer

Country Status (8)

Country Link
US (6) US6894071B2 (en)
EP (3) EP1864660B1 (en)
JP (1) JP4317452B2 (en)
CA (2) CA2466148C (en)
DE (2) DE60235214D1 (en)
DK (2) DK2060259T3 (en)
ES (2) ES2384208T3 (en)
WO (1) WO2003037314A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8648108B2 (en) 2001-11-01 2014-02-11 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
CA2600386A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
EP1891143B1 (en) 2005-06-06 2012-01-11 The University Of British Columbia Polymer-based serum albumin substitute
JP2009526085A (en) * 2006-02-09 2009-07-16 スペクトラム ファーマシューティカルズ インコーポレイテッド Eo9 and treatment of bladder cancer by use of propylene glycol
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
CA2680481C (en) * 2007-03-13 2016-06-21 Spectrum Pharmaceuticals, Inc. Intravesical apaziquone administration following transurethral resection for treating cancer
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
DE212011100034U1 (en) 2010-01-20 2012-07-04 Theracoat Ltd. Material for the treatment of internal cavities
US9186410B2 (en) 2010-03-01 2015-11-17 The University Of British Columbia Derivatized hyperbranched polyglycerols
US9469878B2 (en) * 2010-09-22 2016-10-18 The Board Of Regents Of The University Of Texas System Methods of treating cancer comprising targeting NQO1
EP2734187A1 (en) 2011-07-20 2014-05-28 Theracoat Ltd. Materials and method for treating internal body cavities
CA2853279A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Inc. Cyclohexylamines
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20160318927A1 (en) 2013-12-16 2016-11-03 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US5079257A (en) * 1986-04-17 1992-01-07 Speckamp Willem N Indoloquinone compounds
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5405622A (en) * 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5749845A (en) * 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
US5814330A (en) * 1994-05-18 1998-09-29 Janssen Pharmaceutica, N.V. Mucoadhesive emulsions containing cyclodextrin
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5942209A (en) * 1996-03-11 1999-08-24 Focal, Inc. Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel
US5993846A (en) * 1993-08-13 1999-11-30 Pharmos Corporation Bioadhesive emulsion preparations for enhanced drug delivery
US6005020A (en) * 1997-08-18 1999-12-21 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6039967A (en) * 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
US6123965A (en) * 1996-01-26 2000-09-26 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6156348A (en) * 1996-06-25 2000-12-05 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6894071B2 (en) * 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS6136493B2 (en) 1978-05-19 1986-08-19 Kureha Chemical Ind Co Ltd
NL8001280A (en) * 1980-03-04 1981-10-01 Philips Nv Low-pressure discharge lamp.
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPS60163621A (en) 1984-02-02 1985-08-26 Toshibumi Murakami Production of toilet seat cover made of paper
JPS60163821A (en) 1984-02-03 1985-08-26 Tdk Corp Carrier for pharmaceutical containing ferrite particle
JPH0434964B2 (en) 1985-02-18 1992-06-09 Teijin Ltd
EP0331635A3 (en) 1988-02-29 1990-02-28 The Board Of Regents University Of Texas System Preparations for treating bladder cancer
EP0338679A3 (en) 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
FR2629584B1 (en) 1988-03-31 1993-06-04 France Etat Armement Stabilization device for a projectile has low longitudinal moment of inertia derived from a tube scratch
EP0393575B1 (en) * 1989-04-17 1994-03-16 G.D. Searle &amp; Co. Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
FI84874C (en) 1989-11-02 1992-02-10 Valio Meijerien Foerfarande Foer casing of biologically active aemnen, according to the method framstaelld capsule, och dess anvaendning foder the innehaollande.
US5237466A (en) 1989-11-02 1993-08-17 International Business Machines Corporation Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem
JPH07215843A (en) 1991-05-30 1995-08-15 Recordati Sa Controlled release pharmaceutical composition having bioadhesive property
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
JP3598049B2 (en) 1992-09-18 2004-12-08 山之内製薬株式会社 Hydrogel sustained-release preparation
EP0642797B1 (en) 1993-09-09 2000-05-17 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ES2377126T3 (en) 1994-12-12 2012-03-22 Omeros Corporation Irrigation solution and use thereof for perioperative inhibition of pain, inflammation and / or spasm in a vascular structure
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
JP2967734B2 (en) * 1996-10-18 1999-10-25 日本電気株式会社 A method of forming a thin film
WO1999012547A1 (en) * 1997-09-08 1999-03-18 Theramark Limited Treatment of inflammatory conditions
US6156744A (en) 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
EP0950418A2 (en) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
WO1999065483A1 (en) 1998-05-05 1999-12-23 Astrazeneca Ab Mycobacterial inhibitors
JP2002518315A (en) 1998-06-16 2002-06-25 ベン − グリオン ユニバーシティ オブ ザ ネゲブ Active agent delivery systems and devices based on porous matrix
GB9827034D0 (en) 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2000256182A (en) 1999-03-03 2000-09-19 Kazuhiro Morimoto Antimicrobial formulation
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001091736A3 (en) 2000-05-31 2002-10-17 David James Dooley Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
CA2430363C (en) 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Compounds and their uses
WO2002049630A3 (en) 2000-12-21 2003-05-08 David E Lebwohl Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A3 (en) 2001-07-23 2003-05-08 Brigham & Womens Hospital Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
WO2003092731A1 (en) 2002-05-03 2003-11-13 Novo Nordisk A/S Stabilised solid compositions of modified factor vii
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
WO2004037235A3 (en) 2002-10-24 2004-07-22 Univ Illinois Method and composition for preventing and treating solid tumors
KR101251157B1 (en) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 B-cell reduction using cd37-specific and cd20-specific binding molecules
JP2009526085A (en) 2006-02-09 2009-07-16 スペクトラム ファーマシューティカルズ インコーポレイテッド Eo9 and treatment of bladder cancer by use of propylene glycol

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079257A (en) * 1986-04-17 1992-01-07 Speckamp Willem N Indoloquinone compounds
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5993846A (en) * 1993-08-13 1999-11-30 Pharmos Corporation Bioadhesive emulsion preparations for enhanced drug delivery
US5405622A (en) * 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
US5814330A (en) * 1994-05-18 1998-09-29 Janssen Pharmaceutica, N.V. Mucoadhesive emulsions containing cyclodextrin
US5749845A (en) * 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
US6123965A (en) * 1996-01-26 2000-09-26 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5942209A (en) * 1996-03-11 1999-08-24 Focal, Inc. Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel
US6156348A (en) * 1996-06-25 2000-12-05 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6039967A (en) * 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
US6207180B1 (en) * 1997-04-03 2001-03-27 Thomas B. Ottoboni Intravesical drug delivery
US6005020A (en) * 1997-08-18 1999-12-21 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
US6894071B2 (en) * 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8648108B2 (en) 2001-11-01 2014-02-11 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US9295666B2 (en) 2001-11-01 2016-03-29 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods

Also Published As

Publication number Publication date Type
EP1864660B1 (en) 2010-12-29 grant
US20030133954A1 (en) 2003-07-17 application
EP1864660A2 (en) 2007-12-12 application
DK1864660T3 (en) 2011-02-21 grant
US20050215615A1 (en) 2005-09-29 application
WO2003037314A3 (en) 2003-10-16 application
DE60235214D1 (en) 2010-03-11 grant
EP1864660A3 (en) 2008-04-23 application
CA2466148C (en) 2013-01-08 grant
DE60238798D1 (en) 2011-02-10 grant
EP2060259A1 (en) 2009-05-20 application
US20080166402A1 (en) 2008-07-10 application
CA2466148A1 (en) 2003-05-08 application
US8648108B2 (en) 2014-02-11 grant
JP4317452B2 (en) 2009-08-19 grant
US20120252861A1 (en) 2012-10-04 application
CA2789114C (en) 2014-03-25 grant
US6894071B2 (en) 2005-05-17 grant
US7977369B2 (en) 2011-07-12 grant
EP2060259B1 (en) 2010-01-20 grant
CA2789114A1 (en) 2003-05-08 application
EP1439835A2 (en) 2004-07-28 application
ES2384208T3 (en) 2012-07-02 grant
WO2003037314A2 (en) 2003-05-08 application
US20090076123A1 (en) 2009-03-19 application
JP2005532986A (en) 2005-11-04 application
ES2341922T3 (en) 2010-06-29 grant
DK2060259T3 (en) 2010-05-17 grant

Similar Documents

Publication Publication Date Title
Knox et al. Tryptophan pyrrolase of liver III. Conjugation in vivo during cofactor induction by tryptophan analogues
Modica-Napolitano et al. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells
Hoch-Ligeti et al. Combined carcinogenic effects of dimethyl-nitrosamine and 3-methylcholanthrene in the rat
Detaille et al. Metformin prevents high-glucose–induced endothelial cell death through a mitochondrial permeability transition-dependent process
Oishi et al. Inhibition of Na, K-ATPase and sodium pump by protein kinase C regulators sphingosine, lysophosphatidylcholine, and oleic acid.
US5225404A (en) Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
Yamaoka et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470)
Archer et al. O2 sensing is preserved in mice lacking the gp91 phox subunit of NADPH oxidase
Rosbe et al. Immunohistochemical characterizationof nitric oxide synthase activity in squamous cell carcinoma of the head and neck
Johnston et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer
US6197820B1 (en) Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
Rosenfeldt et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue
US5994410A (en) Therapeutic use of water-soluble fullerene derivatives
Ahlgren et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
Correa et al. Carcinogenesis, apoptosis and cell proliferation
Gautam et al. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI–DNA complexes
Suttorp et al. Lung cell oxidant injury: enhancement of polymorphonuclear leukocyte-mediated cytotoxicity in lung cells exposed to sustained in vitro hyperoxia
Traish et al. Effects of medical or surgical castration on erectile function in an animal model
Kato et al. The functional effect of mild outlet obstruction on the rabbit urinary bladder
Gallegos et al. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium
Neuzil et al. Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability.
Sullivan et al. The expression of drug resistance gene products during the progression of human prostate cancer.
Rodrı́guez et al. Mitochondrial or cytosolic catalase reverses the MnSOD-dependent inhibition of proliferation by enhancing respiratory chain activity, net ATP production, and decreasing the steady state levels of H2O2
Nakagami et al. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells
Paria et al. The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period

Legal Events

Date Code Title Description
AS Assignment

Owner name: SPECTRUM PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NUIJEN, BASTIAAN;PFADENHAUER, ERNIE;BEIJNEN, JOS H.;REEL/FRAME:018382/0084

Effective date: 20030128